SymbioCellTech is a biotechnology company that has developed a patented, proprietary therapy to cure insulin-dependent Type I diabetes Mellitus (T1DM), which is commonly referred to as Type 1 or juvenile onset diabetes. In summary it is been shown that through an intra-abdominal administration of SymbioCellTech Neo-Islets™ (NIs; a cellulartherapeutic) has been shown in multiple animal models of Type 1 Diabetes to result in long-term glucose control with reduced or no need for insulin injections, and with no need for toxic antirejection drugs. The durable blood glucose control along with the absence of an immune response demonstrate that NIs provide protection from autoimmune attacks that ordinarily destroy insulin-producing cells in Type 1 Diabetes, and provide an endogenous and physiologic source of insulin.

Biotechnology

Health Care

Pharmaceutical

Therapeutics

SymbioCellTech, LLC

Christof Westenfelder

Russ Reiss

Jim Horton

Eric Gosink

Axel Zander

Anna Gooch

Leanne Swenson

Travis Manning

The Advisory and Governance Team at SymbioCellTech, LLC is responsible for guiding the company's strategic direction and ensuring compliance with regulatory standards. Comprising experienced board members and strategic advisors, the team offers valuable insights and oversight in the development and commercialization of the company’s groundbreaking Neo-Islets™ therapy, while fostering strong governance practices to support the long-term goals of curing insulin-dependent Type 1 diabetes.

Advisory and Governance Team

Leadership Team

Advisory and Governance Team

About

Team members

Other teams at SymbioCellTech, LLC

Leadership Team